Expression of Smad7 in hepatocellular carcinoma and dysplastic nodules: resistance mechanism to transforming growth factor-beta.
YN Park, KJ Chae, BK Oh, J Choi, KS Choi… - Hepato …, 2004 - europepmc.org
YN Park, KJ Chae, BK Oh, J Choi, KS Choi, C Park
Hepato-gastroenterology, 2004•europepmc.orgResults Smad7 immunoreactivity in tumor cells was found in 25 (61%) advanced HCCs, in
contrast to none of DNs and eHCCs. Smad7 expression was significantly higher in
advanced HCCs with increased TGF-beta1 or no decrease of TGF-beta receptor II compared
to those of corresponding non-HCCs (p= 0.044, p= 0.027). Smad4 expression in stellate
cells was present in 28 (68%) advanced HCCs, which was higher in smaller sized and better
differentiated HCCs. Conclusions Smad7, expressed in tumor cells, is considered to be one …
contrast to none of DNs and eHCCs. Smad7 expression was significantly higher in
advanced HCCs with increased TGF-beta1 or no decrease of TGF-beta receptor II compared
to those of corresponding non-HCCs (p= 0.044, p= 0.027). Smad4 expression in stellate
cells was present in 28 (68%) advanced HCCs, which was higher in smaller sized and better
differentiated HCCs. Conclusions Smad7, expressed in tumor cells, is considered to be one …
Results
Smad7 immunoreactivity in tumor cells was found in 25 (61%) advanced HCCs, in contrast to none of DNs and eHCCs. Smad7 expression was significantly higher in advanced HCCs with increased TGF-beta1 or no decrease of TGF-beta receptor II compared to those of corresponding non-HCCs (p= 0.044, p= 0.027). Smad4 expression in stellate cells was present in 28 (68%) advanced HCCs, which was higher in smaller sized and better differentiated HCCs.
Conclusions
Smad7, expressed in tumor cells, is considered to be one of resistance mechanisms to increased TGF-beta1 in late stage hepatocarcinogenesis, especially in advanced HCCs without reduced TGF-beta receptor II. Smad4, in stellate cells of HCCs, might be involved in the host resistance to hepatocarcinogenesis.
europepmc.org
